During the recent session, ATAI Life Sciences N.V (NASDAQ:ATAI)’s traded shares were 0.44 million, with the beta value of the company hitting 1.19. At the last check today, the stock’s price was $1.59, reflecting an intraday loss of -1.24% or -$0.02. The 52-week high for the ATAI share is $2.85, that puts it down -79.25 from that peak though still a striking 35.22% gain since the share price plummeted to a 52-week low of $1.03. The company’s market capitalization is $308.45M, and the average trade volume was 2.79 million shares over the past three months.
ATAI Life Sciences N.V (ATAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATAI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
ATAI Life Sciences N.V (ATAI) registered a -1.24% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.24% in intraday trading to $1.59, hitting a weekly high. The stock’s 5-day price performance is -3.64%, and it has moved by -29.33% in 30 days. Based on these gigs, the overall price performance for the year is -23.92%.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 73.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, ATAI is trading at a discount of -277.36% off the target high and -277.36% off the low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
In the rating firms’ projections, revenue will increase 159.03% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 250k as predicted by 6 analyst(s).
ATAI Dividends
ATAI Life Sciences N.V is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
The next largest institutional holding, with 2.72 million shares, is of MORGAN STANLEY’s that is approximately 1.7111% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.62 million.
Also, the Mutual Funds coming in first place with the largest holdings of ATAI Life Sciences N.V (ATAI) shares are Morgan Stanley Inst Fund Inc-Inception Port and Vanguard Health Care Index Fund. Data provided on Dec 31, 2024 indicates that Morgan Stanley Inst Fund Inc-Inception Port owns about 511.99 shares. This amounts to just over 0.31 percent of the company’s overall shares, with a $0.81 million market value. The same data shows that the other fund manager holds slightly less at 404.81, or about 0.24% of the stock, which is worth about $0.64 million.
